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Treatment of symptom recurrence after initially successful alcohol septal ablation (ASA) in hypertrophic obstructive cardiomyop-
athy (HOCM) when accompanied by relapse of intracavitary left ventricular pressure gradient (LVG) is guided by the underlying
mechanism. We describe our experience with permanent pacing in three patients with relapse of both LVG and symptoms 7 to
12 months after successful ASA. Even though pressure gradient recurrence was observed at midventricular level, we were able to
achievesymptomaticimprovementandLVGreductionafterrightventricularapexpacinginallthreecases.Theeﬀectonsymptoms
was long lasting—the 6-month followup echo-stress tests conﬁrmed good exercise capacity and lack of provocable LVG. We found
pacing to be a safe and eﬀective treatment option in this clinical scenario. Based on our overall observations, we propose pacing as
a niche treatment for patients with recurrence of LVG at midventricular level after ASA.
1.Introduction
Alcohol septal ablation (ASA) is becoming a popular treat-
ment choice for symptomatic patients with hypertrophic
obstructive cardiomyopathy (HOCM) and resting left ven-
tricular outﬂow tract obstruction gradient (LVOTG) above
50mmHg. The recurrence of symptomatic LVOTG is ap-
proximately 10 percent in the ﬁrst 2 years after ASA [1,
2]. Current hypotheses to explain this recurrence include
possible incomplete remodeling of the septum due to
imprecise location of the iatrogenic lesion, a small infarct
size because of suboptimal ethanol tissue concentration and
an underestimation of existent surgical pathology such as
massive calciﬁcation of the mitral ring [2–4]. To the best
of our knowledge, late recurrence of symptoms due to
“migration” of obstruction to midcavity level following ASA
has not been described in the literature.
Therapeutic options for symptomatic patients with high
residual LVOTG after ASA include surgery, repeat ASA,
permanent pacing, and medical therapy. It is reasonable to
speculate that permanent pacing has a synergistic eﬀect on
LVOTG after ASA and could be attempted before deciding
on a repeat ASA or surgical myectomy.
Here we present our experience with permanent pacing
in three patients with HOCM who had recurrence of
symptoms and LVG after initially successful alcohol septal
ablation.
Sixty-one patients with HOCM who remained symp-
tomatic despite medical treatment underwent alcohol septal
ablation at our institution between October 2004 and Octo-
ber 2007. Only patients with typical systolic anterior motion
(SAM) and invasively measured LVOTG >50mmHg at rest
or at provocation were included. Our technique is described
in a separate article and does not diﬀer considerably from
the one described in the literature [5]. One milliliter of 95%
ethanol per cm of septum thickness was injected through
an OTW balloon catheter after positive pressure reduction
test. If equivocal results were observed, echo contrast was
injected through an inﬂated balloon to delineate the part of
the septum supplied by the septal branch. Long-term success
was deﬁned as resting LVOTG less than 20mmHg and/or
50% reduction of resting and provoked LVOTG matched by2 International Journal of Vascular Medicine
Figure 1:ControlechoofpatientN16monthsafterASA.Thinning
of basal septum is clearly visible (arrow).
relief of the symptoms. Success was achieved in 53 patients
(87%) who were followed for a median of 21 months (3–35).
No mortality was observed at 30 days, 2 patients died at 9
and 18 months, and the causes of death were sudden cardiac
death and terminal heart failure. Recurrence of LVG and
symptoms were observed in 10 patients during the follow-
up period. Six patients were successfully treated with repeat
ASA because of echo ﬁndings of SAM recurrence and three
patients received permanent right ventricular pacing. One
patientrefusedfurthertreatmentanddiedfromheartfailure.
We focus on three patients who share a similar clinical
scenario: late relapse of symptoms due to dynamic obstruc-
tion at midcavity level following ASA despite remodeling
and thinning of the basal septum. All patients underwent
initial ASA at our institution due to eﬀort-limiting angina
refractory to beta blockers. All three had a similar underlying
LV morphology with echocardiography revealing thickening
of the whole septum, typical SAM leading to outﬂow tract
obstruction, and eccentric mitral regurgitation. The septal
thickness at anterior mitral leaﬂet contact was 21, 24, and
20mm, respectively for, patients 1, 2, and 3. Six months
after ASA the result was judged as excellent based on the
disappearance of symptoms and virtual abolishment of
LVOTG at rest echo. Thinning and akinesia of the basal
septum was evident as a proof of well-placed scar (Figure 1).
Patient N1 was a 54-year-old man who presented with
syncope 26 months after ASA and echocardiography at rest
showed left ventricular systolic gradient of 42mmHg at
midcavity level and no SAM. At the index procedure, 2.2mL
of alcohol were injected in the 1st septal perforator artery
with complete resolution of the LVOTG and reduction of the
mitral regurgitation grade. Similarly, patients N2 (a 42-year-
old woman) and N3 (a 61-year-old man) presented 7 and 23
monthsaftersuccessfulASAwithrecurrenceofeﬀortangina.
Invasive assessment of all three patients revealed intracavi-
tary pressure gradient at the level of the papillary muscles
with formation of a distal akinetic chamber (Figure 2). In
all three patients, echocardiography demonstrated marked
scarring of the basal septum as expected late after ASA
(septum thickness 16, 18, and 15mm, resp., for patients 1,
2, and 3) and relatively hypokinetic apex with systolic kissing
of the midsegments of LV. In fact, subaortic obstruction was
eﬀectively converted to a midventricular one. After failure to
control symptoms with beta blockers, we decided to proceed
with permanent pacemaker implantation.
In two patients permanent DDD mode pacemakers were
implanted with passive ﬁxation electrodes positioned at
RV apex and right atrial appendage. In one patient (N1)
VVI pacemaker was implanted after AV node ablation for
high-rate atrial ﬁbrillation. The RV electrode was implanted
aiming at the pig-tail catheter positioned at LV apex. No
estimation of the temporary pacing eﬀect on the LVOTG was
performed. The longest PV interval was adjusted to achieve
full ventricular capture. Ventricular pacing of 99 percent was
achieved in all patients (PV interval of 160msec for DDD
pacemakers).
All three patients had echo at rest and after a stress
test at the 6-month followup The resting LVGs measured
by Doppler echocardiography before ASA, at symptom
recurrenceandat6monthsafterpacingareshowninTable 1.
All three patients were able to achieve 5 METS on a
modiﬁed Bruce protocol at 6-month followup, and echo
detected no LVOTG (deﬁned as velocity >2m/s a) at rest and
after exercise. Functional class signiﬁcantly improved from
NYHA III prior to treatment to NYHA II after-pacing. This
result was sustained for 6 months of followup.
2. Discussion
Despite promising early results, permanent pacing is falling
out of favor as a ﬁrst-line therapy for drug-resistant HOCM
due to its lower success rate demonstrated in randomized
studies as compared to myectomy and ASA [6, 7]. The
reasons for these unsatisfactory results are not clear. A
possible explanation is the inability to achieve full reverse
excitation of the septum in a signiﬁcant proportion of the
patientsduetoshortintrinsicAVintervalortechnicalfactors
suchastheinabilitytoplacetheelectrodeatthetrueRVapex.
Even if some patients do respond to ASA in terms of long-
lasting symptom relief, predictors of success have yet to be
deﬁnitively identiﬁed [8].
The factors leading to ASA failure are also far from clear.
On the basis of studies that followed patients with MRI after
ASA, it can be extrapolated that in a signiﬁcant number of
ablated patients the localization of the infarct is away from
thezoneofcontactbetweentheanteriormitralleaﬂetandthe
septum [4]. Other investigators suggest on the basis of post-
mortemhistologythat,forunknownreasons,evenaproperly
locatedlesioncanleadtopatchyinsteadofdenseﬁbrosiswith
onlymildseptumthinning[3].Inbothcases,theremodeling
of the septum does not lead to outﬂow tract widening.
In contrast to other investigators, we have observed
several cases of recurrence of LVOTG and symptoms well
after the ﬁrst year of followup [9]. This might be related to
the selection of patients or to a technical factor although we
have not found major diﬀerences between our technique and
the one already published in the literature. In the proportion
ofourpatients,distaldisplacementofthelevelofobstruction
due to remodeling of the basal septum led to transformation
of subaoric stenosis into hourglass left ventricle. To the best
ofourknowledge,nosuchcasehasbeenpreviouslydescribed
in the literature.International Journal of Vascular Medicine 3
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Figure 2: Patient N1 presented with syncope and 50mmHg gradient at midcavity level 2 years after ASA. LV-gram before ASA (a) shows
hyperkinetic LV and typical SAM (arrow). LV-gram at 26-month followup (b) is remarkable for the typical dumbbell shape in systole with
formation of distal akinetic camera (thick arrow).
Table 1: Dynamics of LVOTG as measured by echocardiography.
Patient no. LVG at rest before
ASA (mmHg)
L V Ga tr e s t6m oa f t e r
ASA (mmHg)
LVG at recurrence of symptoms
ASA (mmHg)
LVG 6 mo after
pacing (mmHg)
18 0>16 42 >16
25 5>16 60 >16
35 0>16 30 >16
Choice of treatment after ASA failure appears to depend
on the underlying mechanism, with drug therapy rarely
eﬀective in our experience. The small number of cases of
ASA failures makes it highly unlikely that a comparative
study of diﬀerent treatment modalities can be conducted.
Repeat ASA appears to be a logical choice if there is relapse
of LVOTG, SAM and no evidence of eﬀective remodeling of
theseptum. Due tothe lackofreliable criteria forselectionof
responders,currentguidelinesrecommendpacinginHOCM
only in case of coexistent bradycardia/conduction disease or
indicationsforICDplacement[2,8].Thereisalsoagreement
that patients with preexisting bundle branch block who are
candidates for ASA or surgery should receive a pacemaker if
the risk of procedure-related AV block is high [10]. In our
institution, we consider pacing as a ﬁrst-line treatment for
midcavity obstruction because it is relatively non-invasive
and at least 1 publication suggests that it is eﬃcacious [11].
Overall, we have found permanent pacing to be a good
solution even when midcavity obstruction manifested late
after ASA.
3. Conclusions
We found a speciﬁc pattern of progression of HOCM after
successful ASA. In our experience permanent RV pacing
appears to be a safe and eﬀective treatment option with no
major drawbacks. It could be proposed as a niche treatment
for patients with recurrence of LVG at midventricular level
after ASA.
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